Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Caribou Biosciences, Inc. reported a quarterly loss of $0.3 per share, which was better than the Zacks Consensus Estimate of a loss of $0.36, marking an earnings surprise of +16.67% [1] - The company generated revenues of $2.2 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 14.34% [2] - Caribou's shares have increased by approximately 40.9% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.40, with expected revenues of $2.59 million, and for the current fiscal year, it is -$1.73 on revenues of $8.88 million [7] Market Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3] - The estimate revisions trend for Caribou Biosciences was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Biomedical and Genetics industry is currently in the top 34% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]